相似文献
1
Screening for Clonal Hematopoiesis for Mitigating the Risk of Hematopoietic Neoplasms after PRRT.
World J Nucl Med. 2023 Apr 28;22(2):150-151. doi: 10.1055/s-0043-1764308. eCollection 2023 Jun.
2
Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012).
Breast Cancer Res Treat. 2010 Jan;119(2):391-8. doi: 10.1007/s10549-009-0597-5.
3
Clonal hematopoiesis and cardiovascular diseases: role of JAK2V617F.
J Cardiol. 2023 Jan;81(1):3-9. doi: 10.1016/j.jjcc.2022.02.001. Epub 2022 Feb 12.
4
Clonal Hematopoiesis and therapy related MDS/AML.
Best Pract Res Clin Haematol. 2019 Mar;32(1):13-23. doi: 10.1016/j.beha.2019.02.006. Epub 2019 Feb 15.
5
Clonal hematopoiesis in cancer.
Exp Hematol. 2020 Mar;83:105-112. doi: 10.1016/j.exphem.2020.02.001. Epub 2020 Feb 7.
6
Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation.
Bone Marrow Transplant. 2019 Aug;54(8):1189-1197. doi: 10.1038/s41409-018-0413-0. Epub 2018 Nov 30.
7
Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment.
Blood Cancer J. 2023 Jan 4;13(1):5. doi: 10.1038/s41408-022-00773-8.
8
Aging, clonal hematopoiesis and preleukemia: not just bad luck?
Int J Hematol. 2015 Nov;102(5):513-22. doi: 10.1007/s12185-015-1870-5. Epub 2015 Oct 6.
9
[Clonal Hematopoiesis and Solid Cancer].
Gan To Kagaku Ryoho. 2023 Feb;50(2):129-133.
10
[Clonal hematopoiesis: a risk factor for leukemia and cardiovascular disease?].
Ned Tijdschr Geneeskd. 2020 Nov 5;164:D5205.
引用本文的文献
1
Limitations of the radiotheranostic concept in neuroendocrine tumors due to lineage-dependent somatostatin receptor expression on hematopoietic stem and progenitor cells.
Theranostics. 2025 May 25;15(13):6497-6515. doi: 10.7150/thno.113354. eCollection 2025.
本文引用的文献
1
[Lu]Lu-DOTATATE peptide receptor radionuclide therapy-associated myeloid neoplasms: insights from the WHO pharmacovigilance database.
Eur J Nucl Med Mol Imaging. 2022 Aug;49(10):3332-3333. doi: 10.1007/s00259-022-05833-6. Epub 2022 May 6.
2
Mutant - and -Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy.
JCO Precis Oncol. 2022 Jan;6:e2100309. doi: 10.1200/PO.21.00309.
3
Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Epub 2021 Nov 15.
4
Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series.
Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1902-1910. doi: 10.1007/s00259-019-04389-2. Epub 2019 Jun 11.
5
Managing Clonal Hematopoiesis in Patients With Solid Tumors.
J Clin Oncol. 2019 Jan 1;37(1):7-11. doi: 10.1200/JCO.18.00331. Epub 2018 Nov 7.
6
Prospective observational study of Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity.
Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):970-988. doi: 10.1007/s00259-018-3945-z. Epub 2018 Mar 1.
7
Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes.
Cell Stem Cell. 2017 Sep 7;21(3):374-382.e4. doi: 10.1016/j.stem.2017.07.010. Epub 2017 Aug 10.
8
Long-Term Efficacy, Survival, and Safety of [Lu-DOTA,Tyr]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors.
Clin Cancer Res. 2017 Aug 15;23(16):4617-4624. doi: 10.1158/1078-0432.CCR-16-2743. Epub 2017 Apr 20.
9
Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors.
N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427.
10
High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy.
Endocr Relat Cancer. 2016 May;23(5):L17-23. doi: 10.1530/ERC-15-0543. Epub 2016 Mar 1.
Zotero 插件